title: The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
abstract: Lung cancer is the leading cause of death from cancer worldwide that currently has only a few available treatment options in patients with no driver mutations. The therapeutic options for patients with non-small-cell lung cancer (NSCLC) who progress after first-line chemotherapy have been limited from a long time. Docetaxel has remained a cornerstone of second-line treatment for more than 20 years, but it is associated with an unfavorable safety profile. Recently, the results from immunotherapy treatment with anti-PD1 and PD-L1 inhibitors has changed our current knowledge base and increased therapeutic options for patients with NSCLC in the second-line setting. The results of 2 randomized phase III trials assessing nivolumab in lung cancer, Check-Mate-017 and Check-Mate-057, have deeply changed our current clinical practice and raised several discussion points. This paper explores the recent findings about nivolumab for the treatment of NSCLC in the second-line setting by analyzing recent trial findings and discussing their implications in clinical practice and future directions. The paper also summarizes the conclusions from an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
authors.affiliation: Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy. Electronic address: cgridelli@libero.it.
authors.forename: Cesare
authors.initials: C
authors.lastname: Gridelli
authors.affiliation: Department of Cancer Medicine, Gustave-Roussy, Villejuif, Université Paris Sud, Paris, France.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
authors.forename: Julie Renee
authors.initials: JR
authors.lastname: Brahmer
authors.affiliation: Division of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy.
authors.forename: Lucio
authors.initials: L
authors.lastname: Crinò
authors.affiliation: Institut d'Oncologia, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: Enriqueta
authors.initials: E
authors.lastname: Felip
authors.affiliation: Division of Thoracic Oncology, European Insitute of Oncology, Milan, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: de Marinis
mesh_terms: D000465:Algorithms; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003245:Consensus Statements as Topic; D005104:Expert Testimony; D006801:Humans; D007391:International Cooperation; D007558:Italy; D008175:Lung Neoplasms / Q000188:drug therapy*; D008495:Medical Oncology / Q000639:trends; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C423236:CD274 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab
keywords: Anti-PD-1 antibody; Immunotherapy; Nivolumab; PD-L1; Second-line treatment